Key Details
Price
$10.13Annual Revenue
$556.38 MAnnual EPS
-$5.41Annual ROE
76.03%Beta
1.87Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 10, 2019Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S. GAITHERSBURG, Md. , Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi.
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.
Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021.
NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.
COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.
Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md. , Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million.
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
FAQ
- What is the primary business of Novavax?
- What is the ticker symbol for Novavax?
- Does Novavax pay dividends?
- What sector is Novavax in?
- What industry is Novavax in?
- What country is Novavax based in?
- When did Novavax go public?
- Is Novavax in the S&P 500?
- Is Novavax in the NASDAQ 100?
- Is Novavax in the Dow Jones?
- When was Novavax's last earnings report?
- When does Novavax report earnings?
- Should I buy Novavax stock now?